Uncertainty in the aftermath of President Trump's hasty executive order that bars immigrants from seven countries from entering the United States sent the markets tumbling to a sharply lower close with the Dow plummeting 122 points to 19,971. Nasdaq dropped 47 points to 5,613.
On the upside
Calithera Biosciences (Nasdaq: CALA) entered a global collaboration agreement with Incite (Nasdaq: INCY) to develop and commercialize Calithera's small molecule arginase inhibitor CB-1158.
Real Goods Solar (Nasdaq: RGSE) regained compliance with Nasdaq's minimum $2.5 million shareholders' equity requirement.
Dorian (NYSE: LPG) reported lower third quarter earnings and revenue but the stock price rose.
On the downside
Walgreens Boots Alliance (Nasdaq: WBA) has delayed the close of its acquisition of Rite Aid (NYSE: RAD) by six months and has lowered its acquisition offer.
Ocera Therapeutics (Nasdaq: OCRX) reported disappointing results from a STOP-HE Phase 2b study of OCR-002.
The Food and Drug Administration extended the clinical hold on Regulus Therapeutics' (Nasdaq: RGLS) RG-101.
In the broad market, declining issues outpaced advancers by a margin of nearly 5 to 2 on the NYSE and by nearly 7 to 2 on Nasdaq. The broader S&P 500 index dropped 13 points to 2,280. Bitcoin gained $6 to $916.
